Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs

SIMPLE SUMMARY: A proportion of breast tumors bear the oncogenic transmembrane tyrosine kinase protein HER2. Even though therapies that target HER2 have changed the prognosis and quality of life of patients with HER2+ breast tumors, resistance to those therapies is still an important clinical proble...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Rodríguez, Elena, Gandullo-Sánchez, Lucía, Ocaña, Alberto, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750930/
https://www.ncbi.nlm.nih.gov/pubmed/35008318
http://dx.doi.org/10.3390/cancers14010154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750930/
https://www.ncbi.nlm.nih.gov/pubmed/35008318
http://dx.doi.org/10.3390/cancers14010154

Ejemplares similares